Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Prostatic Neoplasms × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroendocrine Tumors 4 Carcinoid Tumor 3 Serotonin Syndrome 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Acromegaly 1

Interventions

Prednisone 101 Docetaxel 79 Leuprolide 72 Abiraterone Acetate 62 enzalutamide 59 bicalutamide 44 Goserelin 44 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 38 Radiotherapy 33 gallium 68 PSMA-11 21 apalutamide 21 abiraterone 21 Magnetic Resonance Spectroscopy 21 Gonadotropin-Releasing Hormone 21 luprolide acetate gel depot 19 sipuleucel-T 18 Androgen Antagonists 18 Triptorelin Pamoate 17 Radiosurgery 17 cabazitaxel 15 Radiotherapy, Intensity-Modulated 14 pembrolizumab 13 cabozantinib 13 Prednisolone 12 Flutamide 12 Dexamethasone 12 Brachytherapy 12 radium Ra 223 dichloride 11 fluciclovine F-18 11 Radiation 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡